Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:38 UTC |
---|
HMDB ID | HMDB0014477 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Methadone |
---|
Description | A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) |
---|
Structure | CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3 |
---|
Synonyms | Value | Source |
---|
6-(Dimethylamino)-4,4-diphenyl-3-heptanone | ChEBI | (+-)-Methadone | ChEBI | 6-dimethylamino-4,4-Diphenyl-3-heptanone | ChEBI | DL-Methadone | ChEBI | Methadonum | ChEBI | (+/-)-methadone | HMDB | (+/-)-methadone hydrochloride | HMDB | DL-Methadone hydrochloride | HMDB | Methadon | HMDB | Methadone HCL | HMDB | Methadone hydrochloride | HMDB | Phenadone hydrochloride | HMDB | Amidone | MeSH, HMDB | Biomet brand OF methadone hydrochloride | MeSH, HMDB | Methadose | MeSH, HMDB | Yamanouchi brand OF methadone hydrochloride | MeSH, HMDB | AddiCare brand OF methadone hydrochloride | MeSH, HMDB | Dolophine | MeSH, HMDB | Generics brand OF methadone hydrochloride | MeSH, HMDB | GlaxoSmithKline brand OF methadone hydrochloride | MeSH, HMDB | Hydrochloride, methadone | MeSH, HMDB | Mallinckrodt brand OF methadone hydrochloride | MeSH, HMDB | Methex | MeSH, HMDB | Pharmascience brand OF methadone hydrochloride | MeSH, HMDB | Phymet | MeSH, HMDB | Physeptone | MeSH, HMDB | Pinadone | MeSH, HMDB | Esteve brand OF methadone hydrochloride | MeSH, HMDB | Metasedin | MeSH, HMDB | Methaddict | MeSH, HMDB | Phenadone | MeSH, HMDB | Rosemont brand OF methadone hydrochloride | MeSH, HMDB | Roxane brand OF methadone hydrochloride | MeSH, HMDB | Symoron | MeSH, HMDB | Biodone | MeSH, HMDB | Martindale brand OF methadone hydrochloride | MeSH, HMDB | Metadol | MeSH, HMDB | Pinewood brand OF methadone hydrochloride | MeSH, HMDB |
|
---|
Chemical Formula | C21H27NO |
---|
Average Molecular Weight | 309.4452 |
---|
Monoisotopic Molecular Weight | 309.209264491 |
---|
IUPAC Name | 6-(dimethylamino)-4,4-diphenylheptan-3-one |
---|
Traditional Name | methadone |
---|
CAS Registry Number | 76-99-3 |
---|
SMILES | CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 |
---|
InChI Identifier | InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3 |
---|
InChI Key | USSIQXCVUWKGNF-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Diphenylmethanes |
---|
Direct Parent | Diphenylmethanes |
---|
Alternative Parents | |
---|
Substituents | - Diphenylmethane
- Aralkylamine
- Gamma-aminoketone
- Ketone
- Tertiary amine
- Tertiary aliphatic amine
- Carbonyl group
- Organooxygen compound
- Organonitrogen compound
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organic oxide
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 235.0 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0059 g/L | Not Available | LogP | 3.93 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 177.7 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Methadone,1TMS,isomer #1 | CC=C(O[Si](C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2267.2 | Semi standard non polar | 33892256 | Methadone,1TMS,isomer #1 | CC=C(O[Si](C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2219.8 | Standard non polar | 33892256 | Methadone,1TMS,isomer #1 | CC=C(O[Si](C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2698.0 | Standard polar | 33892256 | Methadone,1TBDMS,isomer #1 | CC=C(O[Si](C)(C)C(C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2496.3 | Semi standard non polar | 33892256 | Methadone,1TBDMS,isomer #1 | CC=C(O[Si](C)(C)C(C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2458.3 | Standard non polar | 33892256 | Methadone,1TBDMS,isomer #1 | CC=C(O[Si](C)(C)C(C)(C)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 | 2780.5 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Methadone EI-B (Non-derivatized) | splash10-00di-9310000000-d71659ee33e210178a79 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Methadone CI-B (Non-derivatized) | splash10-03di-0009000000-c583dd769bf5998ac160 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Methadone EI-B (Non-derivatized) | splash10-00di-9310000000-d71659ee33e210178a79 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Methadone CI-B (Non-derivatized) | splash10-03di-0009000000-c583dd769bf5998ac160 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methadone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0uk9-9080000000-1cd26d01442b30c05512 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methadone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methadone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methadone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Methadone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-00di-9210000000-7542d8c3f742c7713c13 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-QTOF , positive-QTOF | splash10-03di-0029000000-43d5c8da88c1aa260682 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-QTOF , positive-QTOF | splash10-014i-0090000000-31b8655a24b30962bd8c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-QTOF , positive-QTOF | splash10-01b9-0590000000-9894da52e88d32034318 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-QTOF , positive-QTOF | splash10-014i-0940000000-fedb75bd4c80c6c4fea9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-QTOF , positive-QTOF | splash10-0gb9-0940000000-a27b5f75aab7fac8931d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-014i-0090000000-1d4283f6dffa11b765e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-03di-0019000000-416fca50b212d00b968c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-014i-0090000000-ad95925610aed55afe91 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0aor-1980000000-6d4d0adc4c8db177eaad | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-1920000000-0548504791642aa3b2e0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-2920000000-dd2ce03c02a54aa24f83 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-3910000000-1af5f56241eabde05700 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-03di-0019000000-015df6e52b9d5ebe5cb2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-014i-0091000000-b328f3740a7ca4485324 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0aor-0980000000-24074e0b5c722d7279c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-1920000000-5477eb89abafab290dd1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-2920000000-b4ffdf7888e464422c0c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-0a4i-3910000000-6053da2e4586dbcae300 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methadone LC-ESI-ITFT , positive-QTOF | splash10-014i-0090000000-0863c3130ca5df5f25b6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 10V, Positive-QTOF | splash10-03di-0069000000-144e893c575a6cb0ceb3 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 20V, Positive-QTOF | splash10-0229-8093000000-72ef33a6770239211ec3 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 40V, Positive-QTOF | splash10-0aw9-9780000000-930cd0f8dcbecbc72f1b | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 10V, Negative-QTOF | splash10-0a4i-0019000000-3418a56694229e2c6595 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 20V, Negative-QTOF | splash10-0a4i-3069000000-10bb89e35854fe0680a5 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methadone 40V, Negative-QTOF | splash10-00fu-9180000000-abf68f949ff2ecf35fcc | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00333 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00333 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00333 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 3953 |
---|
KEGG Compound ID | C07163 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Methadone |
---|
METLIN ID | Not Available |
---|
PubChem Compound | Not Available |
---|
PDB ID | Not Available |
---|
ChEBI ID | 167309 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. [PubMed:8018740 ]
- Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. [PubMed:11064485 ]
- Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. [PubMed:12405865 ]
- Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. [PubMed:16185211 ]
- Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. [PubMed:17313907 ]
- Leander JD, Wood CR: Metkephamid effects on operant behavior. Peptides. 1982 Sep-Oct;3(5):771-3. [PubMed:7177922 ]
|
---|